| Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases. | |
| | |
MedLine Citation:
|
PMID: 1968894 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We examined 122 patients with inflammatory bowel disease treated with salicylazosulfapyridine. Forty-two (34.5%) had adverse effects that led to discontinuation of therapy in 14 (11.5%). In 33 patients the effects appeared to be dose dependent. The plasma sulfapyridine levels in patients exhibiting gastrointestinal side effects were significantly higher than in patients with no adverse effects (41.0 +/- 20.3 and 23.8 +/- 14.8 micrograms/ml respectively, P less than 0.001). Plasma sulfapyridine levels were significantly higher in slow than in fast acetylators (31.5 +/- 17.1 vs. 22.2 +/- 17.1 micrograms/ml). Slow acetylators had three times as many side effects as fast acetylators; however this difference was not statistically significant. |
| | |
Authors:
|
G Rahav; E Zylber-Katz; D Rachmilewitz; M Levy |
Related Documents
:
|
17592074 - Serial biomarker measurements in ambulatory patients with chronic heart failure: the im... 21106544 - Tenting area reflects disease severity and prognosis in patients with non-ischaemic dil... 15090704 - Usefulness of the percentage of plasma lymphocytes as a prognostic marker in patients w... 20466224 - Risk of venous thromboembolism in patients with borderline quantitative d-dimer levels. 15529374 - Prolonged bleeding time and lupus anticoagulant: a second paradox in the antiphospholip... 15892594 - Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patie... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Israel journal of medical sciences Volume: 26 ISSN: 0021-2180 ISO Abbreviation: Isr. J. Med. Sci. Publication Date: 1990 Jan |
Date Detail:
|
Created Date: 1990-04-16 Completed Date: 1990-04-16 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0013105 Medline TA: Isr J Med Sci Country: ISRAEL |
Other Details:
|
Languages: eng Pagination: 31-4 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Hadassah University Hospital, Mt. Scopus, Israel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetylation Adolescent Adult Aged Chronic Disease Dose-Response Relationship, Drug Female Humans Inflammatory Bowel Diseases / drug therapy*, genetics, metabolism Male Middle Aged Nausea / chemically induced Phenotype Retrospective Studies Sulfanilamides / blood* Sulfapyridine / blood*, metabolism Sulfasalazine / administration & dosage, adverse effects*, metabolism Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Sulfanilamides; 144-83-2/Sulfapyridine; 599-79-1/Sulfasalazine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Plasma noradrenaline as an index of sympathetic tone in coronary arterial disease: the confounding i...
Next Document: Current status of symptomatic therapy of allergic rhinitis